Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations, Disclosure

Discontinued Operations, Disclosure

3 Months Ended

Mar. 31, 2017

3. DISCONTINUED OPERATIONS:

In efforts to streamline operations and expenses the Company elected to discontinue the Dr. Pave and Dr. Pave Worldwide entities during 2015. The financial results of these events are represented in discontinued operations included in the March 31, 2017 and 2016 financial statements.

The operating results of the discontinued operations of Dr. Pave and Dr. Pave Worldwide for the three months ended March 31, 2017 and 2016 are summarized below:

	2017		2016
Revenue	$	--	$	--
Expense		--		2,004
Net Loss, before taxes		--		(2,004)
Income tax benefit		--		--
Net Loss, net of tax	$	--	$	(2,004)

There were no assets or liabilities from discontinued operations as of March 31, 2017 and December 31, 2016.